UCB Presents Latest Epilepsy Research at International Congress
At a major international event focused on epilepsy, UCB is proud to showcase 26 scientific abstracts, including two key oral presentations. This reflects UCB's robust commitment to advancing research for individuals living with epilepsy, particularly for those diagnosed with conditions like Dravet Syndrome and Lennox-Gastaut Syndrome.
Highlights from UCB’s Research
Among the findings presented, an open-label extension study reported on the long-term safety of FINTEPLA (fenfluramine) in patients with Dravet syndrome or Lennox-Gastaut syndrome. This research highlighted both the sustained benefits and the positive global functioning outcomes for children and adults alike.
Exploration of Developmental and Epileptic Encephalopathies
UCB's data delve into developmental and epileptic encephalopathies (DEEs). A qualitative study pinpointed challenges in accurately diagnosing DEEs within adult care settings. This research included insights from caregivers about the impact of unpredictable seizures and disruptive behaviors, revealing the daily struggles that these individuals face.
Understanding Prolonged Seizures
Another focus was the definition and consequences of prolonged seizures on both patients and caregivers. The findings suggest that the burden of managing these conditions can often escalate into emergencies, underscoring the necessity for continued education and resource accessibility for caregivers.
The Significance of Early Diagnosis
Pivotal to UCB’s mission is the understanding that early and accurate diagnosis can dramatically improve the quality of life for patients with DEEs. UCB’s investigation into barriers faced by healthcare professionals in identifying these conditions in adults underscores an urgent need for better diagnostic frameworks.
Researching Patient and Caregiver Experiences
The latest surveys highlight the significant psychological and practical impacts of seizure unpredictability on both patients and their caregivers. Nearly half of those surveyed indicated that disruptive behaviors acted as a barrier to effective daily functioning and overall well-being.
Future Developments and Innovations
Diagnosis and management strategies are an integral part of UCB’s strategy moving forward. Increased collaborations with caregivers, healthcare professionals, and researchers will continue to shape innovative solutions aimed at overcoming the challenges present in epilepsy treatments.
UCB’s Commitment to Epilepsy Care
Dimitrios Bourikas, Global Medical Head of DEE and Epilepsy at UCB, emphasized their commitment to supporting individuals living with epilepsy and improving care standards. Their ongoing research efforts at the International Epilepsy Congress reflect UCB's mission to innovate and enhance patient support.
Frequently Asked Questions
What is UCB's role in epilepsy research?
UCB actively engages in research to improve treatments and diagnostics for epilepsy, focusing on innovative solutions tailored to patient needs.
What is FINTEPLA and its purpose?
FINTEPLA (fenfluramine) is a medication used to treat seizures in patients with Dravet and Lennox-Gastaut syndromes, emphasizing long-term safety and efficacy.
How does UCB support caregivers?
UCB's research identifies caregiver challenges and aims to provide education and resources to help manage the complexities of epilepsy.
What insights were shared regarding prolonged seizures?
Research indicates that prolonged seizures can significantly affect quality of life, often leading to emergency care and necessitating strategic management plans.
How does UCB plan to improve diagnostic practices?
UCB is committed to advancing diagnostic frameworks, highlighted by collaborative studies with healthcare professionals to close existing gaps in epilepsy identification.
